GSTP1 (Glutathione S-transferase pi 1) [3F2C2]

GSTs (α, κ, μ, π, σ, θ, ζ, and ω) are identified, while only GST-α, -μ, and -π are described in the central nervous system. GSTP1 (GSTπ) is overexpressed in early stages of carcinogenesis and can be used as a neoplastic marker in tumor tissues. GSTP1 directly inhibits TRAF2 and JNK but not NF-κB. GSTP1 polymorphisms affect substrate selectivity and stability, and the oxidative milieu in dopaminergic neurons, which increases the susceptibility to Parkinson’s disease. Adenocarcinomas of the stomach, kidney, uterus and ovary, as well as squamous cell tumors of the head and neck, melanomas, and carcinoid tumors of the lung all demonstrate reactivity with this antibody.